Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

Tiffany Guana Department of Pharmaceutical Services, University of California, San Francisco Medical Center, San Francisco, CA, USACorrespondence[email protected]

https://orcid.org/0000-0003-4332-0891

Mimi Loa Department of Pharmaceutical Services, University of California, San Francisco Medical Center, San Francisco, CA, USA

Rebecca Younga Department of Pharmaceutical Services, University of California, San Francisco Medical Center, San Francisco, CA, USA

Weiyun Aib Department of Medicine, Division of Hematology/BMT, University of California, San Francisco, San Francisco, CA, USA

Fouad Boulbolc Community Cancer Institute, Community Medical Center, Clovis, CA, USA

Hanson Mouanoutouad Department of Medicine, University of California, San Francisco, Fresno Campus, Fresno, CA, USA

Raymond Chue School of Pharmacy, University of California, San Francisco, San Francisco, CA, USA

Charalambos Andreadisb Department of Medicine, Division of Hematology/BMT, University of California, San Francisco, San Francisco, CA, USA

Lawrence Kaplanb Department of Medicine, Division of Hematology/BMT, University of California, San Francisco, San Francisco, CA, USA

Haifaa Abdulhaqd Department of Medicine, University of California, San Francisco, Fresno Campus, Fresno, CA, USA

Bita Fakhrib Department of Medicine, Division of Hematology/BMT, University of California, San Francisco, San Francisco, CA, USA

show all

Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

Information for

Open access

Opportunities

Help and information

Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin

Disclosure statement

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature